Online inquiry

IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14151MR)

This product GTTS-WQ14151MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14151MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9800MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ12400MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ9023MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ7301MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ8942MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ11242MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ8557MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ2189MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW